Peter S. Schmid
Ashfield Street
London, ENG, United Kingdom
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 130 publications
TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10.
Journal: Future oncology (London, England)
Published: July 31, 2026
PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer.
Journal: Cell reports
Published: June 04, 2026
ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
Journal: Annals of surgical oncology
Published: March 12, 2026
Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 11, 2026
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 02, 2026
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
Journal: The New England journal of medicine
Published: January 21, 2026
OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy.
Journal: Future oncology (London, England)
Published: December 29, 2025
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.
Journal: NPJ breast cancer
Published: December 15, 2025
Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 26, 2025
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
Journal: Annals of surgical oncology
Published: October 03, 2025
Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis.
Journal: Cancer science
Published: September 08, 2025
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 12, 2025
Last Updated: 09/26/2026